The One Simple Reason Investors Should Still Steer Clear Away From Valeant

Published: Aug 25, 2017

Over the past two years, only a small handful of publicly traded companies have the distinction of losing more than 90% of their value. Drugmaker Valeant Pharmaceuticals (NYSE:VRX) finds itself in that mix, having shed about 94% of its value since peaking in early August 2015 at $264 a share.

Valeant has faced a cadre of issues along the way, including allegations of wrongdoing by one of its online drug distributors, Philidor Rx Services, and has taken heat for its drug-pricing practices.

Back to news